Navigation Links
US Oncology Reports First Quarter 2008 Results
Date:5/7/2008

e required to estimate a value that would be allocated to goodwill in a hypothetical purchase transaction using an estimate of the segment's fair value as the purchase price. This estimation process also requires the identification and valuation of intangible assets that have either increased in value or have been created through Company initiatives and investments. Any value assigned to identified intangible assets reduces the amount attributable to goodwill.

In addition to the goodwill impairment charge, we recognized restructuring and other charges which relate primarily to employee severance costs amounting to $1.3 million in the first quarter of 2008. These amounts are excluded from Adjusted EBITDA.

During the first quarter of 2008 and fourth quarter of 2007 we also recognized an unrealized loss of $16.0 million and $11.6 million, respectively, related to the Company's interest rate swap, due to decreasing LIBOR rates. Because the interest rate swap is not accounted for as a cash flow hedge, changes in the fair value of the instrument are reported currently in earnings. Although cash flow hedge accounting is no longer applied to the interest rate swap, the Company believes the swap, economically, remains a hedge against the variability of interest payments on a portion of its outstanding floating rate debt. The non-cash charge on the interest rate swap is excluded from Adjusted EBITDA.

Cash Flow

During the first quarter of 2008, operating cash flow was $50.9 million, compared to $23.7 million in the first quarter of 2007. The increase is primarily due to improved receivable collections and the election to pay interest due March 15, 2008 on the Holdings notes, in kind. Operating cash flow decreased $23.3 million from $74.2 million in the fourth quarter of 2007 due to payments made to physicians, earned in 2007 under programs that encourage their efficient use of capital and services in our pharmaceutical services segment, as well as s
'/>"/>

SOURCE US Oncology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
3. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
4. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
5. US Oncology to Report 2007 Third Quarter Earnings Results
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
8. Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals
9. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
10. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
11. National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National Greening Your School Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 It is almost ... sprint or walk for healthier and happier kids. The ... participate in the 4th Annual Miami Children’s Hospital 5K Run/Walk. ... http://www.hyundaihopeonwheels.org , The 5K will take place ... will be outside of Coral Gables City Hall located at ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Clinical trial ... data on the Edema clinical trial scenario. This report ... trials on Edema. It includes an overview of the ... site of trial conduction across the globe. The databook ... their phase, trial status, prominence of the sponsors and ...
(Date:9/18/2014)... PA (PRWEB) September 18, 2014 ... announces the launch of Good Neighbor Pharmacy University, ... access information that will educate and empower pharmacy ... “As the healthcare industry continues to evolve, Good ... as we deliver resources and tools to help ...
(Date:9/18/2014)... September 18, 2014 CD-adapco, the largest ... software, today announced its new partnership with Ben Ainslie ... CD-adapco simulation tool, STAR-CCM+® in the design of its ... participation in the 35th America’s Cup taking place in ... the America’s Cup is sustainability, the set of restrictive ...
(Date:9/18/2014)... more vegetables and drink less sugar, according to a ... it,s still not enough, the study goes on to ... comes to eating healthier at school , The research ... status, may inform a child,s diet. , The study ... education were 85 per cent more likely to eat ...
Breaking Medicine News(10 mins):Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Good Neighbor Pharmacy University Keeps Pharmacists Ahead of the Curve 2Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Kids eat better if their parents went to college 2
... a study published in the recent issue of Annals ... exercise //as preconditions to prevent and control diabetes type ... cost effective to control diabetes through rigorous exercise and ... diabetes reduces the body’s ability to store calories, resulting ...
... at the annual meeting of the American Academy of Orthopedic ... back pain may be the result of several problems other ... restrict the effect of a surgery. The study that had ... National Spine Network, US, said that patients who had other ...
... 100 patients at an ear , nose and throat clinic ... snoring // shouldn't expect to receive a diagnosis of obstructive ... examination alone instead an overnight sleep testing needs to be ... ,For the study, physicians evaluated the patients with a ...
... now that after delivery depressions, that had plagued new mothers all ... the delivery. As a result of this belief, many pregnant women ... new study that comes in the recent issue of British Medical ... to Deirdre Murphy of Dundee University, who had led the team ...
... twins and their mothers to see if there was a ... // of life and children's antisocial behavior by age 7 ... have increased problems with conduct and more antisocial behavior . ... the twins' birth and the likeliness of antisocial behavior in ...
... to treat agitation in patients with Alzheimer's or dementia, ... findings of a recent study .// ,For ... Twenty-six of the patients received quetiapine (an antipsychotic also ... also known as Exelon), and 29 received a placebo. ...
Cached Medicine News:
(Date:9/18/2014)... , Sept. 18, 2014 MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today that it has entered into a ... MiMedx will provide its dehydrated human amnion/chorion membrane ... non- exclusively on a private label basis. ...
(Date:9/18/2014)... 18, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has removed the ... PEGPH20 in SWOG,s ongoing Phase 1b/2 clinical trial ... investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in ... with metastatic pancreatic adenocarcinoma.  The study will resume ...
(Date:9/18/2014)... -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company ... announced today that it has appointed Mr. Christopher ... of Clinical Development. During his extensive career ... successful global clinical operations teams, in the US and ... development of numerous therapeutics and diagnostics across a broad ...
Breaking Medicine Technology:MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... (ASX: PGL; Nasdaq: PGLA) today announced additional,data from the ... this,year. This data was presented at the 58th Annual ... Diseases in Boston, USA(1). As the Phase 2 ... data analysis described in this presentation was performed to,evaluate ...
... overall rate of sustained virologic response in ... long-acting interferons in ... Albuferon non-responder study presented at the, Annual Meeting of the American Association for the Study ... ...
Cached Medicine Technology:Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 2Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: